[go: up one dir, main page]

PE20010741A1 - Derivados de piperazina como antagonistas de taquicininas - Google Patents

Derivados de piperazina como antagonistas de taquicininas

Info

Publication number
PE20010741A1
PE20010741A1 PE2000001068A PE0010682000A PE20010741A1 PE 20010741 A1 PE20010741 A1 PE 20010741A1 PE 2000001068 A PE2000001068 A PE 2000001068A PE 0010682000 A PE0010682000 A PE 0010682000A PE 20010741 A1 PE20010741 A1 PE 20010741A1
Authority
PE
Peru
Prior art keywords
alkyl
members
tachycinins
antagonists
methyl
Prior art date
Application number
PE2000001068A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Giuseppe Guercio
Yves St-Denis
Fabio Romano Di
Antonella Ursini
Riccardo Giovannini
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20010741A1 publication Critical patent/PE20010741A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIPERAZINA DE FORMULA I, DONDE R ES HALOGENO, ALQUILO C1-C4; R1 ES H, ALQUILO C1-C4; R2 ES H, ALQUILO C1-C4, ALQUENILO C2-C6, CICLOALQUILO C3-C7; R1 Y R2 JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R3 ES TRIFLUOROMETILO, ALQUILO C1-C4, ALCOXILO C1-C4, TRIFLUOROMETOXI, HALOGENO; R4 ES H, (CH2)qR7, (CH2)rCO(CH2)pR7; R5 ES H, ALQUILO C1-C4, COR6; R6 ES H, OH, AMINO, METILAMINO, DIMETILAMINO, HETEROARILO DE 5 MIEMBROS CON 1-3 O, S, N; HETEROARILO DE 6 MIEMBROS CON 1-3 N; R7 ES H, OH, NR8R9; R8 Y R9 SON H, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO POR OH, AMINO; R10 ES H, ALQUILO C1-C4; R10 Y R2 SON CICLOALQUILO C3-C7; m Y n SON 0-3; p Y r SON 0-4; q ES 1-4; CUANDO R1 Y R2 JUNTO CON N Y C FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; i)m ES 1-2; ii)CUANDO m ES 1; R NO ES F; iii)CUANDO m ES 2, LOS DOS R NO SON F. SON COMPUESTOS PREFERIDOS (3,5-BIS-TRIFLUOROMETIL-BENCIL)METIL-AMIDA DEL ACIDO 2-(4-FLUORO-2-METIL-FENIL)-PIPERAZIN-1-CARBOXILICO, CLORHIDRATO DE (3,5-BIS-TRIFLUORO-BENCIL)-METIL-AMIDA DEL ACIDO 2-(S)-(4-FLUORO-2-METIL-FENIL)-4-(PIPERIN-4-CARBONIL)-PIPERAZINA-1-CARBOXILICO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DE TAQUICININAS (SUSTANCIA P, NEUROCININAS) Y PUEDEN SER UTIL PARA EL TRATAMIENTO DE LA DEPRESION, ANSIEDAD, PANICO
PE2000001068A 1999-10-07 2000-10-06 Derivados de piperazina como antagonistas de taquicininas PE20010741A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923748.9A GB9923748D0 (en) 1999-10-07 1999-10-07 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20010741A1 true PE20010741A1 (es) 2001-07-18

Family

ID=10862304

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001068A PE20010741A1 (es) 1999-10-07 2000-10-06 Derivados de piperazina como antagonistas de taquicininas

Country Status (33)

Country Link
US (6) US6951861B1 (es)
EP (3) EP1218359B1 (es)
JP (1) JP4776844B2 (es)
KR (2) KR100857671B1 (es)
CN (1) CN100413850C (es)
AR (2) AR025975A1 (es)
AT (3) ATE435215T1 (es)
AU (1) AU768780B2 (es)
BR (1) BR0014541A (es)
CA (1) CA2386515C (es)
CO (1) CO5251467A1 (es)
CY (2) CY1110172T1 (es)
CZ (1) CZ302340B6 (es)
DE (3) DE60042501D1 (es)
DK (3) DK1460066T3 (es)
ES (3) ES2329130T3 (es)
GB (1) GB9923748D0 (es)
HK (1) HK1052506B (es)
HU (1) HUP0203136A3 (es)
IL (2) IL148964A0 (es)
MX (1) MXPA02003515A (es)
MY (1) MY130907A (es)
NO (1) NO323776B1 (es)
NZ (2) NZ518144A (es)
PE (1) PE20010741A1 (es)
PL (1) PL201191B1 (es)
PT (3) PT1460066E (es)
SI (3) SI1218359T1 (es)
TN (1) TNSN00194A1 (es)
TR (1) TR200200936T2 (es)
TW (1) TWI225485B (es)
WO (1) WO2001025219A2 (es)
ZA (1) ZA200202589B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
DE10209145A1 (de) * 2002-03-01 2003-09-04 Bayer Cropscience Ag Halogenbenzole
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
JP4079727B2 (ja) 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ　グループ　リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
WO2004110996A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
KR100877641B1 (ko) * 2003-11-28 2009-01-09 미쓰비시 타나베 파마 코퍼레이션 피페리딘 화합물 및 그의 제조 방법
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
JP5510040B2 (ja) * 2010-04-28 2014-06-04 セントラル硝子株式会社 光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
SG11201404880UA (en) 2012-02-22 2014-09-26 Leo Pharma As Novel neurokinin 1 receptor antagonist compounds
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
US10421716B2 (en) 2014-12-23 2019-09-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
US10399949B2 (en) 2015-12-07 2019-09-03 Kissei Pharmaceutical Co., Ltd. NK1 receptor antagonist
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
ES3009607T3 (en) 2017-06-30 2025-03-27 Chase Therapeutics Corp Nk-1 antagonist compositions and methods for use in treating depression
CN112153968A (zh) 2017-10-05 2020-12-29 生物基因公司 制备α-羧酰胺吡咯烷衍生物的工艺

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
ATE195867T1 (de) 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
AU3085895A (en) 1994-07-26 1996-02-22 Sankyo Company Limited N-phenylated amide and urea derivatives
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CN1183770A (zh) 1994-12-23 1998-06-03 卡尔·托马博士公司 哌嗪衍生物,含该化合物的药物,其用途以及制法
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0921801A1 (en) * 1996-04-03 1999-06-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU707139B2 (en) 1996-04-03 1999-07-01 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036888A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
ATE265209T1 (de) * 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
EP0942730A1 (en) 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating bipolar disorders
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
JP2001513561A (ja) 1997-08-27 2001-09-04 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害薬
JP2001524465A (ja) 1997-11-24 2001-12-04 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害剤としての置換β−アラニン誘導体
ES2257089T3 (es) * 1998-12-14 2006-07-16 Astellas Pharma Inc. Derivados de piperazina.
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
NO20021637L (no) 2002-06-06
MXPA02003515A (es) 2002-09-02
NO20021637D0 (no) 2002-04-05
US6951861B1 (en) 2005-10-04
NO323776B1 (no) 2007-07-02
DE60012031D1 (de) 2004-08-12
EP1218359A2 (en) 2002-07-03
DK1454901T3 (da) 2009-01-12
US6642240B2 (en) 2003-11-04
ZA200202589B (en) 2003-08-27
KR20020038800A (ko) 2002-05-23
WO2001025219A2 (en) 2001-04-12
US7071196B2 (en) 2006-07-04
JP4776844B2 (ja) 2011-09-21
WO2001025219A3 (en) 2001-12-13
DE60042501D1 (de) 2009-08-13
EP1454901B1 (en) 2008-09-03
AR077414A2 (es) 2011-08-24
CZ302340B6 (cs) 2011-03-23
DE60040176D1 (de) 2008-10-16
KR20070112308A (ko) 2007-11-22
HK1052506A1 (zh) 2003-09-19
ATE435215T1 (de) 2009-07-15
KR100817373B1 (ko) 2008-03-27
NZ518144A (en) 2004-04-30
DK1460066T3 (da) 2009-11-02
CA2386515A1 (en) 2001-04-12
EP1460066A1 (en) 2004-09-22
SI1460066T1 (sl) 2009-12-31
ATE407125T1 (de) 2008-09-15
CZ20021166A3 (cs) 2002-11-13
TWI225485B (en) 2004-12-21
AU7913900A (en) 2001-05-10
HUP0203136A2 (hu) 2003-02-28
JP2003511377A (ja) 2003-03-25
IL148964A0 (en) 2002-11-10
US20040209893A1 (en) 2004-10-21
US20060122192A1 (en) 2006-06-08
GB9923748D0 (en) 1999-12-08
BR0014541A (pt) 2002-09-17
ES2312917T3 (es) 2009-03-01
PL356261A1 (en) 2004-06-28
ES2222927T3 (es) 2005-02-16
CN1391564A (zh) 2003-01-15
PT1454901E (pt) 2008-12-12
US20030028021A1 (en) 2003-02-06
DE60012031T2 (de) 2005-07-07
HK1066537A1 (en) 2005-03-24
US7345041B2 (en) 2008-03-18
HUP0203136A3 (en) 2003-03-28
HK1065798A1 (en) 2005-03-04
KR100857671B1 (ko) 2008-09-08
CO5251467A1 (es) 2003-02-28
SI1218359T1 (en) 2005-02-28
EP1218359B1 (en) 2004-07-07
MY130907A (en) 2007-07-31
PT1218359E (pt) 2004-10-29
IL148964A (en) 2007-02-11
DK1218359T3 (da) 2004-10-18
AR025975A1 (es) 2002-12-26
CY1110172T1 (el) 2015-01-14
AU768780B2 (en) 2004-01-08
SI1454901T1 (sl) 2009-02-28
US7625904B2 (en) 2009-12-01
HK1052506B (zh) 2008-12-19
NZ531127A (en) 2005-11-25
EP1460066B1 (en) 2009-07-01
CY1110104T1 (el) 2015-01-14
PT1460066E (pt) 2009-09-10
CA2386515C (en) 2011-06-07
US20040048862A1 (en) 2004-03-11
US20080249108A1 (en) 2008-10-09
ES2329130T3 (es) 2009-11-23
TNSN00194A1 (en) 2005-11-10
TR200200936T2 (tr) 2002-07-22
PL201191B1 (pl) 2009-03-31
EP1454901A1 (en) 2004-09-08
ATE270664T1 (de) 2004-07-15
CN100413850C (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20221264A1 (es) Inhibidores de egfr
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
RU2323927C2 (ru) Производные 1-сульфонил-4-аминоалкоксииндола и фармацевтическая композиция, обладающая активностью модулятора 5-нт6 рецептора
AR029614A1 (es) Derivados de 4-fenil-piridina, su uso, un proceso para prepararlos, y medicamentos que los contienen
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20010219A1 (es) AGONISTAS ß-ADRENORRECEPTORES
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
PE58399A1 (es) Atropisomeros de 3-aril-4(3h)-quinazolinonas
RU2006135111A (ru) Производные тиазола
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
AR040333A1 (es) Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20080136A1 (es) Arilsulfonamidas sustituidas como agentes antivirales

Legal Events

Date Code Title Description
FD Application declared void or lapsed